Nguyen Xuan Canh, Nguyen Van Khoi, Tran Minh Thong, Maurea Simone, Salvatore Marco
Unit of PET/CT and Cyclotron, Choray Hospital, Ho Chi Minh City, Vietnam.
Center of Oncology, Choray Hospital, Ho Chi Minh City, Vietnam.
World J Nucl Med. 2014 May;13(2):112-9. doi: 10.4103/1450-1147.139142.
To assess the prognostic value of maximum standardized uptake value (maxSUV) of the primary tumor (maxSUVpt), maxSUV of whole-body tumors (maxSUVwb) and sum of maximum standardized uptake value (sumaxSUV) measured by the sum of maxSUVs of the primary tumor, metastatic lymph nodes, and metastatic lesions per each organ on fluoro-D-glucose-positron emission tomography/computed tomography in advanced non-small cell lung cancer (NSCLC). Eighty-three patients (49 male, 34 female) with advanced NSCLC were enrolled. Seventeen patients had Stage IIIA, 21 Stage IIIB, and 45 Stage IV. maxSUVpt, maxSUVwb, sumaxSUV, age, gender, tumor-cell type, T stage, N stage, overall stage, primary tumor size, and specific treatment were analyzed for correlation with overall survival. Median follow-up duration was 13 months. Fifty patients were dead during a median follow-up time of 11 months and 33 patients were alive with a median time of 15 months. Univariate analysis revealed that overall survival was significantly correlated with sumaxSUV (≥35 vs. <35, P = 0.004), T stage (T4 vs. T1-T3, P = 0.025), overall stage (IV vs. III, P = 0.002), gender (male vs. female, P = 0.029) and specific treatment (no vs. yes, P = 0.011). maxSUVpt and maxSUVwb were not correlated with overall survival with P value of 0.139 and 0.168, respectively. Multivariate analysis identified sumaxSUV, T stage, gender, and specific treatment as independent prognostic indicators. Patients with a sumaxSUV of ≥35 were 1.921 times more likely to die than those with a sumaxSUV of < 35 (P = 0.047). Median survival time was 14 months for patients with sumaxSUV ≥ 35 compared with 20 months for those with sumaxSUV < 35. In patients with metastatic NSCLC, sumaxSUV with cut-off of 35 was much more significant for survival prognosis (P = 0.021). sumaxSUV is a new prognostic measure, independent of tumor stage, gender, and specific treatment in advanced NSCLC. sumaxSUV may be better than maxSUVpt and maxSUVwb in prediction of survival. A large prospective cohort study is necessary to validate these results.
评估氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描中,原发性肿瘤的最大标准化摄取值(maxSUVpt)、全身肿瘤的maxSUV(maxSUVwb)以及通过原发性肿瘤、转移淋巴结和每个器官转移病灶的maxSUV总和测得的最大标准化摄取值总和(sumaxSUV),在晚期非小细胞肺癌(NSCLC)中的预后价值。纳入83例晚期NSCLC患者(49例男性,34例女性)。17例为IIIA期,21例为IIIB期,45例为IV期。分析maxSUVpt、maxSUVwb、sumaxSUV、年龄、性别、肿瘤细胞类型、T分期、N分期、总分期、原发性肿瘤大小和具体治疗与总生存期的相关性。中位随访时间为13个月。50例患者在中位随访时间11个月时死亡,33例患者存活,中位时间为15个月。单因素分析显示,总生存期与sumaxSUV(≥35 vs. <35,P = 0.004)、T分期(T4 vs. T1-T3,P = 0.025)、总分期(IV vs. III,P = 0.002)、性别(男性vs.女性,P = 0.029)和具体治疗(否vs.是,P = 0.011)显著相关。maxSUVpt和maxSUVwb与总生存期无相关性,P值分别为0.139和0.168。多因素分析确定sumaxSUV、T分期、性别和具体治疗为独立预后指标。sumaxSUV≥35的患者死亡可能性是sumaxSUV<35患者的1.921倍(P = 0.047)。sumaxSUV≥35的患者中位生存时间为14个月,而sumaxSUV<35的患者为20个月。在转移性NSCLC患者中,sumaxSUV临界值为35时对生存预后的影响更为显著(P = 0.021)。sumaxSUV是一种新的预后指标,独立于晚期NSCLC的肿瘤分期、性别和具体治疗。在预测生存期方面,sumaxSUV可能优于maxSUVpt和maxSUVwb。需要进行大规模前瞻性队列研究来验证这些结果。